Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
|Articles|February 18, 2018
New Potential Way to Combat Influenza Highlights AJPB Week in Review
Author(s)AJPB staff
Top articles of the week from The American Journal of Pharmacy Benefits.
Advertisement
5. Migraines May Be Key Risk Factor for Cardiovascular Diseases
In addition to myocardial infarction and stroke, migraines may also be linked to an increased risk for venous thromboembolism and atrial fibrillation.
4. Threat of Drug-Resistant E. Coli Increases with Pediatric Antibiotic Prescriptions
Antibiotics may become ineffective treating E. Coli if antibiotic resistance continues to increase among children.
3. Experimental Drug Fails in Alzheimer's Disease Trial
An investigational PDE9A inhibitor did not show efficacy in patients with Alzheimer’s disease.
2. Influenza Vaccine More Effective Than Previously Projected
The 2017/2018 influenza vaccine was more effective in the United States than Canada and Australia.
1. UV Light Could Fight the Spread of Influenza
Ultraviolet C light could be safely harnessed to kill influenza microbes.
Advertisement
Related to this article
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
William J. Peppard, PharmD, explains how emerging suzetrigine findings after knee arthroplasty connect opioid stewardship with functional recovery and the pharmacist’s role in ensuring treatment access.
Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
In adults with type 2 diabetes at high cardiovascular (CV) risk, the oral GLP-1 RA also improved HbA1C and weight, with less hypoglycemia but more GI events.
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
4
Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
5